Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth

Group 1 - Blueprint Medicines Corporation (BPMC) is a prominent developer of therapies targeting mast cell disorders and genetically determined cancers [1] - BPMC has recently expanded the application of Ayvakit (Avapritinib) for treating systemic mastocytosis, both advanced and indolent forms [1] - The company's pipeline includes BLU-808, indicating ongoing development in innovative therapies [1]